NCT06679985 2026-04-13
A Trial of Casdozokitug in Combination With Toripalimab Plus Bevacizumab in Participants With Unresectable and/or Locally Advanced or Metastatic Hepatocellular Carcinoma
Coherus Oncology, Inc.
Phase 2 Active not recruiting
Clinical Trials
21 trialsNCT07481058 2026-03-20
KC1036 in Combination With PD-1 Antibody and Platinum-based Chemotherapy for First-line Advanced Esophageal Cancer
Beijing Konruns Pharmaceutical Co., Ltd.
Phase 2 Recruiting
NCT05441475 2026-02-25
A Phase 2, Open-Label Study of ABSK-011 Combined Atezolizumab or SOC in HCC Patients
Abbisko Therapeutics Co, Ltd
Phase 2 Enrolling by invitation
NCT07314723 2026-01-02
9MW2821 Combined With Toripalimab in Perioperative Patients With Urothelial Cancer
Mabwell (Shanghai) Bioscience Co., Ltd.
Phase 2 Recruiting
NCT05386888 2025-10-02
A Trial of GFH018 and Toripalimab in Combination With Concurrent Chemoradiotherapy in Stage III NSCLC Chemoradiotherapy in Stage III NSCLC
Genfleet Therapeutics (Shanghai) Inc.
Phase 2 Completed
NCT06178159 2025-10-01
DV in Combination With Pertuzumab With or Without Toripalimab Neoadjuvant Therapy With HER2-positive Breast Cancer
RemeGen Co., Ltd.
Phase 2 Recruiting
NCT06623136 2025-09-26
A Study of ES102 in Combination With Toripalimab in Subjects With Advanced Non-small Cell Lung Cancer
Elpiscience Biopharma, Ltd.
Phase 2 Recruiting
NCT05934331 2025-09-12
A LM-302 Combination With Other Anti-Tumor Therapies Phase ll Study
LaNova Medicines Limited
Phase 2 Recruiting
NCT06823427 2025-03-21
9MW2821 + Toripalimab vs 9MW2821 for 1st Line Locally Advanced or Metastatic Urothelial Carcinoma
Mabwell (Shanghai) Bioscience Co., Ltd.
Phase 2 Recruiting
NCT06873854 2025-03-13
A Study of LM-108 in Combination With Toripalimab in Subjects With Advanced Solid Tumours
LaNova Medicines Limited
Phase 2 Not yet recruiting
NCT06642545 2025-02-17
Efficacy and Safety Study of Disitamab Vedotin + RC148 vs. Albumin-Paclitaxone ± Toripalimab in HR-/HER2-low Breast Cancer
RemeGen Co., Ltd.
Phase 2 Recruiting
NCT05031494 2025-01-06
A Study to Assess YH003 in Combination with Toripalimab(anti-PD-1 MAb) Injection in Patients with Cancers
Eucure (Beijing) Biopharma Co., Ltd
Phase 2 Completed
NCT06105008 2024-08-23
Study of Disitamab Vedotin With Toripalimab Verus Disitamab Vedotin in Hormone Receptor Positive, HER2-low Locally Advanced or Metastatic Breast Cancer
RemeGen Co., Ltd.
Phase 2 Withdrawn
NCT06378177 2024-06-27
A Study of LVGN6051 Combination Therapy in Patient With Head and Neck Squamous Cell Carcinoma (HNSCC)
Lyvgen Biopharma Holdings Limited
Phase 2 Recruiting
NCT06389006 2024-05-23
To Evaluate the Efficacy and Safety of Disitamab Vedotin Combined With Toripalimab Sequential Chemotherapy as Neoadjuvant Treatment in Patients With HR-positive, HER2-low Breast Cancer
RemeGen Co., Ltd.
Phase 2 Recruiting
NCT06111274 2024-04-11
A Phase 2 Study of ABSK021 in Patients With Advanced Pancreatic Cancer
Abbisko Therapeutics Co, Ltd
Phase 2 Recruiting
NCT06155383 2023-12-14
Perioperative Disitamab Vedotin Plus Toripalimab and XELOX in Gastric or Gastroesophageal Junction Adenocarcinoma.
RemeGen Co., Ltd.
Phase 2 Recruiting
NCT05212922 2023-03-20
YH001
Eucure (Beijing) Biopharma Co., Ltd
Phase 2 Withdrawn
NCT04169672 2023-03-02
Study of Surufatinib Single Agent or Surufatinib Combined With Toripalimab in Patients With Advanced Solid Tumors
Hutchmed
Phase 2 Completed
NCT03848611 2020-07-09
CM082 and JS001 in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC).
AnewPharma
Phase 2 Unknown
NCT03904719 2020-07-09
CM082 and JS001 in Patients With Advanced Small-cell Lung Cancer (SCLC)
AnewPharma
Phase 2 Unknown